---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-24-000105"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:47:10.792709+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Maravai reports Q3 loss of $176M on $154.2M goodwill impairment; acquires Officinae Bio DNA/RNA business

## Summary
- Q3 revenue $65.2M (down 2.5% YoY); net loss $(176.0)M includes $154.2M goodwill impairment.
- Adjusted EBITDA $12.7M vs $11.9M in Q3 2023.
- FY2024 revenue guidance lowered to $255-265M (from prior outlook).
- Agreed to acquire Officinae Bio's DNA/RNA business (AI-driven platform); close expected early 2025.
- Nucleic Acid Production revenue $49.9M (down 2.5% YoY); Biologics Safety Testing $15.3M (down 2.5%).

## SEC filing metadata
- accession: 0001823239-24-000105
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323924000105/0001823239-24-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323924000105/mrvi-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-24-000105
- JSON: https://secwatch.observer/filing/0001823239-24-000105.json
- Plain text: https://secwatch.observer/filing/0001823239-24-000105.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.